The integration of anthracyclines in the treatment of advanced ovarian cancer
- 1 July 2001
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 11 (s1) , 34-38
- https://doi.org/10.1046/j.1525-1438.11.s1.2.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.Journal of Clinical Oncology, 1997
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian CarcinomaAmerican Journal of Clinical Oncology, 1992
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973